PMV PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
PMV PHARMACEUTICALS, INC. (PMVP) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 79.82 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-14
- PMV PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-06-30 was 34.21K shares, a 96.04% decline year-over-year.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-03-31 was 171.02K shares, a 75.00% decline year-over-year.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 205.22K shares, a 95.49% decline from fiscal 2024.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 4.55M shares, a 6376.63% increase from fiscal 2023.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 70.29K shares, a 28.00% decline from fiscal 2022.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 97.62K shares, a 125.24% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 79.82K shares 10-Q · filed 2026-08-14 | |||
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | 0.00 shares derived: sum of 2 quarters · filed 2026-03-06 | 34.21K shares derived: sum of 3 quarters · filed 2026-03-06 | 205.22K shares 10-K · filed 2026-03-06 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 34.21K shares derived: sum of 2 quarters · filed 2025-11-12 | 205.22K shares 10-Q · filed 2025-11-12 | 212.98K shares derived: sum of 4 quarters · filed 2025-11-12 |
| 2025-06-30 | 34.21K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 205.22K shares 10-Q · filed 2025-08-07 | 212.98K shares derived: sum of 3 quarters · filed 2025-08-07 | 3.21M shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 171.02K shares 10-Q · filed 2025-05-09 | 178.77K shares derived: sum of 2 quarters · filed 2025-05-09 | 3.17M shares derived: sum of 3 quarters · filed 2025-05-09 | 4.04M shares derived: sum of 4 quarters · filed 2025-05-09 |
| 2024-12-31 | 7.76K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | 3.00M shares derived: sum of 2 quarters · filed 2025-03-03 | 3.87M shares derived: sum of 3 quarters · filed 2025-03-03 | 4.55M shares 10-K · filed 2025-03-03 |
| 2024-09-30 | 3.00M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 3.86M shares derived: sum of 2 quarters · filed 2024-11-07 | 4.54M shares 10-Q · filed 2024-11-07 | 4.59M shares derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | 864.54K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 1.55M shares 10-Q · filed 2024-08-08 | 1.59M shares derived: sum of 3 quarters · filed 2024-08-08 | 1.59M shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 684.01K shares 10-Q · filed 2024-05-09 | 724.32K shares derived: sum of 2 quarters · filed 2024-05-09 | 726.05K shares derived: sum of 3 quarters · filed 2024-05-09 | 738.98K shares derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | 40.31K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | 42.04K shares derived: sum of 2 quarters · filed 2024-02-29 | 54.96K shares derived: sum of 3 quarters · filed 2024-02-29 | 70.29K shares 10-K · filed 2024-02-29 |
| 2023-09-30 | 1.73K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 14.65K shares derived: sum of 2 quarters · filed 2023-11-09 | 29.98K shares 10-Q · filed 2023-11-09 | 43.31K shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 12.92K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | 28.25K shares 10-Q · filed 2023-08-09 | 41.58K shares derived: sum of 3 quarters · filed 2023-08-09 | 117.54K shares derived: sum of 4 quarters · filed 2023-08-09 |
| 2023-03-31 | 15.33K shares 10-Q · filed 2023-05-10 | 28.66K shares derived: sum of 2 quarters · filed 2023-05-10 | 104.62K shares derived: sum of 3 quarters · filed 2023-05-10 | |
| 2022-12-31 | 13.33K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | 89.28K shares derived: sum of 2 quarters · filed 2023-03-01 | 97.62K shares 10-K · filed 2023-03-01 | |
| 2022-09-30 | 75.96K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 84.30K shares 10-Q · filed 2022-11-08 | ||
| 2022-06-30 | 8.34K shares 10-Q · filed 2022-08-09 | |||
| 2021-12-31 | 226.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | 15.56K shares derived: sum of 2 quarters · filed 2022-03-01 | 24.13K shares derived: sum of 3 quarters · filed 2022-03-01 | 43.34K shares 10-K · filed 2022-03-01 |
| 2021-09-30 | 15.33K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | 23.90K shares derived: sum of 2 quarters · filed 2021-11-12 | 43.12K shares 10-Q · filed 2021-11-12 | 42.82K shares derived: sum of 4 quarters · filed 2021-11-12 |
| 2021-06-30 | 8.57K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | 27.78K shares 10-Q · filed 2021-08-13 | 27.48K shares derived: sum of 3 quarters · filed 2021-08-13 | |
| 2021-03-31 | 19.21K shares 10-Q · filed 2021-05-14 | 18.91K shares derived: sum of 2 quarters · filed 2021-05-14 | ||
| 2020-12-31 | -300.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-03 | 48.02K shares 10-K · filed 2021-03-03 | ||
| 2020-09-30 | 48.32K shares 10-Q · filed 2020-11-13 | |||
| 2019-12-31 | 133.59K shares 10-K · filed 2021-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |